Stock 0NLV VITA 34 AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings VITA 34 AG London S.E.

Equities

0NLV

DE000A0BL849

End-of-day quote London S.E.
Other stock markets
 		5-day change 1st Jan Change
- PTS -.--% Intraday chart for VITA 34 AG -.--% -.--%
Jun. 01 VITA 34 AG Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 30 VITA 34 AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • With regards to fundamentals, the enterprise value to sales ratio is at 0.95 for the current period. Therefore, the company is undervalued.
  • Sales forecast by analysts have been recently revised upwards.
  • For the past twelve months, EPS forecast has been revised upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

1st Jan change Capi. Investor Rating ESG Refinitiv
VITA 34 AG Stock VITA 34 AG
-.--% 84.02M -
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+19.82% 84.94B
C+
CVS HEALTH CORPORATION Stock CVS Health Corporation
-25.28% 74.07B
B-
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
-1.34% 26.15B
C+
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
+4.56% 18.03B
A-
LABCORP HOLDINGS INC. Stock Labcorp Holdings Inc.
-9.29% 17.38B
B
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
+4.52% 16.01B
A-
NATERA, INC. Stock Natera, Inc.
+78.16% 13.7B
C-
TENET HEALTHCARE CORPORATION Stock Tenet Healthcare Corporation
+77.84% 13.13B
C+
PURE HEALTH HOLDING Stock Pure Health Holding
-26.14% 12.74B - -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. V3V Stock
  4. 0NLV Stock
  5. Ratings VITA 34 AG